Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Share Options

31 Aug 2011 14:44

RNS Number : 3548N
Angle PLC
31 August 2011
 



For immediate release

31 August 2011

 

ANGLE plc ("the Company")

 

Share Options

 

Reflecting the current developments within the business and the need to ensure ongoing incentivisation of the management team, the Remuneration Committee has cancelled certain existing share options over ordinary shares in the Company issued to staff and directors and issued new share options at the current market price.

 

Following the cancellation of 940,422 existing share options and the issue of 1,856,000 new share options, the Company now has outstanding options issued to staff and directors over a total of 2,055,397 ordinary shares being 5.8% of the shares currently in issue.

 

The exercise price for the new share options is set at the current mid market price of 25.75 pence per share. Vesting of the share options will be subject to a performance condition that the share price together with any dividend payments has risen by at least 50% from the current market price. The share options will vest over a three year period and expire ten years after issue.

 

Following the new issue of share options, the total number of share options held by the directors and senior management of the Company are:

 

Options (% issued)

Before issue

After issue

Increase

Andrew Newland, Chief Executive

648,675 (1.8%)

950,000 (2.7%)

301,325 (0.8%)

Ian Griffiths, Finance Director

247,619 (0.7%)

500,000 (1.4%)

252,381 (0.7%)

Shane Booth, Parsortix CEO

33,810 (0.1%)

250,000 (0.7%)

216,190 (0.6%)

 

 

The non-executive directors do not hold share options.

 

ANGLE Chairman, Garth Selvey, commented:

"The new options are part of a revitalised remuneration scheme which takes account of changes within the Company and replace four sets of options awarded between 2005 and 2007. The new options also take into account salary waived by senior members of the Company."

 

 

For further information:

ANGLE plc

01483 685830

Garth Selvey, Chairman

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Collins Stewart Europe Limited

Matt Goode

0207 523 8350

Buchanan

Lisa Baderoon, Catherine Breen

020 7466 5000

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

0207 653 0030

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDKDDQNBKDNFN
Date   Source Headline
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results
27th Jan 201610:42 amRNSNotice of Interim Results
25th Jan 20167:00 amRNSUKE publishes evaluation of Parsortix
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication
12th Nov 20152:17 pmRNSISSUE OF SHARE OPTIONS
14th Oct 20157:00 amRNSPatent Grant
30th Sep 20155:50 pmRNSResult of AGM
28th Sep 20157:00 amRNSOvarian cancer results
24th Sep 20157:00 amRNSProstrate cancer study published PLOS ONE Journal
9th Sep 20157:00 amRNSBREAST CANCER RESULTS PRESENTED AT CDX CONFERENCE
8th Sep 20153:54 pmRNSAnnual Report and Accounts and Notice of AGM
26th Aug 20151:48 pmRNSIssue of Equity and Total Voting Rights
23rd Jul 20157:00 amRNSFinal Results
20th Jul 20157:00 amRNSNotification of Preliminary Results
8th Jul 20157:00 amRNSAppointment Of Scientific Adviser
11th Jun 20157:00 amRNSBarts Prostate Cancer Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.